Inventor · disambiguated record
Scott Hammond
Also filed as: HAMMOND SCOTT · HAMMOND SCOTT A · HAMMOND SCOTT ALAN
16 granted patents·16 pending applications·611 citations·filing 2006–2024
94Inventor score
Files withMEDIMMUNE LLC16MEDIMMUNE LTD10ASKLEPIOS BIOPHARMACEUTICAL INC1HAMMOND SCOTT1HAMMOND SCOTT A1
Top patents by PatentIndex Score
32 records- 0195US9493565B2Targeted binding agents against B7-H1MEDIMMUNE LTD·Filed 2014·Granted Nov 15, 2016·50 cites·8 claims
- 0295US8779108B2Targeted binding agents against B7-H1QUEVA CHRISTOPHE·Filed 2010·Granted Jul 15, 2014·452 cites·31 claims
- 0394US9938356B2Binding molecules specific for CD73 and uses thereofMEDIMMUNE LTD·Filed 2015·Granted Apr 10, 2018·26 cites·9 claims
- 0494US9738723B2Humanized anti-OX40 antibodies and uses thereofMEDIMMUNE LLC·Filed 2015·Granted Aug 22, 2017·20 cites·24 claims
- 0593US10457732B2Bispecific binding proteins and uses thereofMEDIMMUNE LLC·Filed 2017·Granted Oct 29, 2019·10 cites·12 claims
- 0691US10287362B2Binding molecules specific for CD73 and uses thereofMEDIMMUNE LTD·Filed 2018·Granted May 14, 2019·10 cites·15 claims
- 0791US9308257B2Protein formulationSHARMA SR MONIKA S·Filed 2008·Granted Apr 12, 2016·27 cites·22 claims
- 0890US10400039B2Targeted binding agents against B7-H1MEDIMMUNE LTD·Filed 2016·Granted Sep 3, 2019·8 cites·8 claims
- 0989USRE49908EBispecific binding proteins and uses thereofMEDIMMUNE LLC·Filed 2021·Granted Apr 9, 2024·1 cites·43 claims
- 1089US11279759B2Bispecific binding proteins and uses thereofMEDIMMUNE LLC·Filed 2019·Granted Mar 22, 2022·4 cites·19 claims
- 1187US2025074986A1Bispecific binding proteins and uses thereofMEDIMMUNE LLC·Filed 2024·Application pending·0 cites
- 1281US10556968B2Binding molecules specific for CD73 and uses thereofMEDIMMUNE LTD·Filed 2019·Granted Feb 11, 2020·2 cites·8 claims
- 1380US2023235062A1Targeted binding agents against b7-h1MEDIMMUNE LTD·Filed 2022·Application pending·0 cites
- 1479US2023340152A1Binding molecules specific for cd73 and uses thereofMEDIMMUNE LTD·Filed 2022·Application pending·0 cites
- 1575US2022251204A1Bispecific binding proteins and uses thereofMEDIMMUNE LLC·Filed 2021·Application pending·0 cites
- 1672US11525012B2Binding molecules specific for CD73 and uses thereofMEDIMMUNE LTD·Filed 2019·Granted Dec 13, 2022·0 cites·6 claims
- 1768US9718870B2OX40L fusion proteins and uses thereofMEDIMMUNE LLC·Filed 2015·Granted Aug 1, 2017·1 cites·36 claims
- 1867US11518809B2Targeted binding agents against B7-H1MEDIMMUNE LTD·Filed 2019·Granted Dec 6, 2022·0 cites·11 claims
- 1964US2025213726A1Therapeutic adeno-associated virus using codon optimized nucleic acid encoding alpha-glucosidase (gaa) for treating pompe disease, with signal peptide modificationsASKLEPIOS BIOPHARMACEUTICAL INC·Filed 2023·Application pending·0 cites
- 2062US2024075160A1Combination therapies for treatment of cancerMEDIMMUNE LLC·Filed 2023·Application pending·0 cites
- 2160US11939382B2Bispecific PD-1 and TIGIT binding proteins and uses thereofMEDIMMUNE LLC·Filed 2022·Granted Mar 26, 2024·0 cites·20 claims
- 2256US10150815B2Method of treating cancer with humanized anti-OX40 antibodiesMEDIMMUNE LLC·Filed 2017·Granted Dec 11, 2018·0 cites·8 claims
- 2356US2019169303A1Humanized Anti-OX40 Antibodies and Uses ThereofMEDIMMUNE LLC·Filed 2018·Application pending·0 cites
- 2453US2024044901A1New method to pronostic lung cancerINST NAT SANTE RECH MED·Filed 2022·Application pending·0 cites
- 2550US2022332818A1Bispecific antibody targeting pd-1 and tim-3MEDIMMUNE LLC·Filed 2022·Application pending·0 cites
- 2647US2016215051A1Protein formulationMEDIMMUNE LLC·Filed 2016·Application pending·0 cites
- 2744US2019241659A1Bispecific fusion polypeptides and methods of use thereofMEDIMMUNE LLC·Filed 2018·Application pending·0 cites
- 2842US2008044413A1EphA2 BiTE molecules and uses thereofHAMMOND SCOTT A·Filed 2006·Application pending·0 cites
- 2938US2013035249A1Methods and compositions for detecting and treating cea-expressing cancersMEDIMMUNE LLC·Filed 2010·Application pending·0 cites
- 3036US2014242081A1Dosing regimens for treatment of cea-expressing cancersHAMMOND SCOTT·Filed 2011·Application pending·0 cites
- 3135US2016347848A1Therapeutic combinations and methods for treating neoplasiaMEDIMMUNE LTD·Filed 2016·Application pending·0 cites
- 3231US2017015758A1Compositions And Methods For Modulating And Redirecting Immune ResponsesMEDIMMUNE LLC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Scott Hammond files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →